This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2025 Aug 21;393(8):827.

doi: 10.1056/NEJMc2509454.

Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

Jesus Rivera-Esteban¹, Víctor Valverde-Salazar, José L Calleja¹

Affiliations

PMID: 40834310
DOI: 10.1056/NEJMc2509454

Comment

Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

Jesus Rivera-Esteban et al. N Engl J Med. 2025.

. 2025 Aug 21;393(8):827.

doi: 10.1056/NEJMc2509454.

Authors

Jesus Rivera-Esteban¹, Víctor Valverde-Salazar, José L Calleja¹

Affiliation

¹ Hospital Universitario Puerta de Hierro Majadahonda, Madrid.

PMID: 40834310
DOI: 10.1056/NEJMc2509454

No abstract available

PubMed Disclaimer

Comment on

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Sanyal AJ, et al. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. N Engl J Med. 2025. PMID: 40305708 Clinical Trial.

References

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.